Study of Dextromethorphan in OCD and Related Disorders

Part of paid clinical trials in Stanford, California.

Sponsor
Stanford University
Study ID
NCT04899687
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Body Dysmorphic Disorders
  • Illness Anxiety Disorder
  • Obsessive-Compulsive Disorder
  • Somatic Symptom Disorder

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Fluoxetine — DRUG
    Fluoxetine 20mg (or previously prescribed dose) will be taken once daily by mouth for 8 weeks
  • Dextromethorphan — DRUG
    Dextromethorphan, an over-the-counter cough suppressant, will be taken by mouth twice daily for four weeks of the study, starting at 15mg per dose, and increasing weekly as tolerated to a maximum of 60mg per dose.

Study Details

The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.

Key Dates

Start date
Jan 20, 2022
Status verified
May 2026
Primary completion
Apr 1, 2027
Completion
Dec 1, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Group A: fluoxetine then fluoxetine plus dextromethorphan
    Group A participants will take fluoxetine 20mg (or prior dose) daily for 4 weeks, and will then continue fluoxetine while adding over the counter dextromethorphan, with doses increasing weekly as tolerated, for 4 weeks.
  • Experimental: Group B: fluoxetine plus dextromethorphan then fluoxetine
    Group B participants will take fluoxetine 20mg (or prior dose) daily together with over the counter dextromethorphan, with doses increasing weekly as tolerated, for 4 weeks, and then will stop dextromethorphan, continuing fluoxetine alone for 4 weeks.

Primary Outcome Measure

Improvement in OCD or related disorder symptoms as measured by the Y-BOCS [ Time Frame: Change from baseline will be assessed at 4 weeks and at 8 weeks. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford UniversityStanfordCalifornia94304
Alessa Gaeta, BA
[email protected]
650-723-4095
Peter van Roessel, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Stanford, CA

By research site
Stanford University· Stanford, CA

Related Studies